Structure-based approach for the study of thyroid hormone receptor binding affinity and subtype selectivity

References

• Apriletti, J. W., Ribeiro, R. C. J., Wagner, R. L., Feng, W., Webb, P., Kushner, P. J., … Baxter, J. D. (1998). Molecular and structural biology of thyroid hormone receptors. Clinical & Experimental Pharmacology & Physiology, 25, S2–S11. doi:10.1111/j.1440-1681.1998.tb02293.x
   Google Scholar
• Bayly, C. I., Cieplak, P., Cornell, W., & Kollman, P. A. (1993). A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: The RESP model. The Journal of Physical Chemistry, 97, 10269–10280. doi:10.1021/j100142a004
   Web of Science ®Google Scholar
• Bhadoriya, K. S., Sharma, M. C., Jain, S. V., Raut, G. S., & Rananaware, J. R. (2013). Three-dimensional quantitative structure–activity relationship (3D-QSAR) analysis and molecular docking-based combined in silico rational approach to design potent and novel TRPV1 antagonists. Medicinal Chemistry Research, 22, 2312–2327. doi:10.1007/s00044-012-0226-4
   Web of Science ®Google Scholar
• Chiellini, G., Apriletti, J. W., Yoshihara, H. A., Baxter, J. D., Ribeiro, R. C., & Scanlan, T. S. (1998). A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chemistry & Biology, 5, 299–306. doi:10.1016/S1074-5521(98)90168-5
   PubMed Web of Science ®Google Scholar
• Chiellini, G., Nguyen, N. H., Yoshihara, H. A. I., & Scanlan, T. S. (2000). Improved synthesis of the iodine-free thyromimetic GC-1. Bioorganic & Medicinal Chemistry Letters, 10, 2607–2611. doi:10.1016/S0960-894X(00)00531-X
   PubMed Web of Science ®Google Scholar
• Clark, M., Cramer, R. D., Opdenbosch, N. V., & Iii, R. D. C. (1989). Validation of the general purpose tripos 5.2 force field. Journal of Computational Chemistry, 10, 982–1012. doi:10.1002/jcc.540100804
   Web of Science ®Google Scholar
• Cramer, R. D., Bunce, J. D., Patterson, D. E., & Frank, I. E. (1988). Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quantitative Structure-Activity Relationships, 7, 18–25. doi:10.1002/qsar.19880070105
   Google Scholar
• Darimont, B. D., Wagner, R. L., Apriletti, J. W., Stallcup, M. R., Kushner, P. J., Baxter, J. D., … Yamamoto, K. R. (1998). Structure and specificity of nuclear receptor-coactivator interactions. Genes & Development, 12, 3343–3356. doi:10.1101/gad.12.21.3343
   PubMed Web of Science ®Google Scholar
• DeGroot, L. J., Larsen, P. R., & Hennemann, G. (1996). The thyroid and its diseases. New York: WB Saunders Company/Churchill Livingstone.
   Google Scholar
• Dolinsky, T. J., Nielsen, J. E., McCammon, J. A., & Baker, N. A. (2004). PDB2PQR: An automated pipeline for the setup of Poisson–Boltzmann electrostatics calculations. Nucleic Acids Research, 32, W665–W667. doi:10.1093/nar/gkh381
   PubMed Web of Science ®Google Scholar
• Du, J., Qin, J., Liu, H., & Yao, X. (2008). 3D-QSAR and molecular docking studies of selective agonists for the thyroid hormone receptor beta. Journal of Molecular Graphics & Modelling, 27, 95–104. doi:10.1016/j.jmgm.2008.03.003
   PubMed Web of Science ®Google Scholar
• Eswar, N., Webb, B., Marti-Renom, M. A., Madhusudhan, M. S., Eramian, D., Shen, M. Y., … Sali, A. (2007). Comparative protein structure modeling using Modeller. Current Protocols in Bioinfomatics, 15, 578–585. doi:10.1002/0471140864.ps0209s50
   Google Scholar
• Goodford, P. J. (1985). A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. Journal of Medicinal Chemistry, 28, 849–857. doi:10.1021/jm00145a002
   PubMed Web of Science ®Google Scholar
• Greenspan, F. (2001). The thyroid gland. In F. Greenspan & D. Gardner (Eds.), Basic & clinical endocrinology (6th ed.). Lange Medical Books, McGraw-Hill.
   Google Scholar
• Hao, M., Li, Y., Wang, Y., Yan, Y., Zhang, S., Li, G., & Yang, L. (2011). Combined 3D-QSAR, molecular docking, and molecular dynamics study on piperazinyl-glutamate-pyridines/pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation. Journal of Chemical Information & Modeling, 51, 2560–2572. doi:10.1021/ci2002878
   PubMed Web of Science ®Google Scholar
• Johansson, C., Vennström, B., & Thorén, P. (1998). Evidence that decreased heart rate in thyroid hormone receptor-R1-deficient mice is an intrinsic defect. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 275, R640–R646. Retrieved from http://ajpregu.physiology.org/content/275/2/R640.long
   PubMed Web of Science ®Google Scholar
• Julio, C., Miguel, G., & Michael, F. (2006). 2D Autocorrelation modeling of the negative inotropic activity of calcium entry blockers using Bayesian-regularized genetic neural networks. Bioorganic & Medicinal Chemistry, 14, 3330–3340. doi:10.1016/j.bmc.2005.12.048
   PubMed Web of Science ®Google Scholar
• Kahaly, G. J., Matthews, C. H., Mohr-Kahaly, S., Richards, C. A., & Chatterjee, V. K. K. (2002). Cardiac involvement in thyroid hormone resistance. The Journal of Clinical Endocrinology & Metabolism, 87, 204–212. doi:10.1210/jcem.87.1.8170
   PubMed Web of Science ®Google Scholar
• Kirkpatrick, P. (2004). Virtual screening: Gliding to success. Nature Reviews Drug Discovery, 3, 299–299. doi:10.1038/nrd1364
   Web of Science ®Google Scholar
• Lazar, M. A. (1993). Thyroid hormone receptors: Multiple forms, multiple possibilities. Endocrine Reviews, 14, 184–193. doi:10.1210/er.14.2.18
   PubMed Web of Science ®Google Scholar
• Li, F., Xie, Q., Li, X., Li, N., Chi, P., Chen, J., … Hao, C. (2010). Hormone activity of hydroxylated polybrominated diphenyl ethers on human thyroid receptor-beta: In vitro and in silico investigations. Environmental Health Perspectives, 118, 602–606. doi:10.1289/ehp.0901457
   PubMed Web of Science ®Google Scholar
• Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., … Chambon, P. (1995). The nuclear receptor superfamily: The second decade. Cell, 83, 835–839. doi:10.1016/0092-8674(95)90199-X
   PubMed Web of Science ®Google Scholar
• Mao, Y., Li, Y., Hao, M., Zhang, S., & Ai, C. (2012). Docking, molecular dynamics and quantitative structure-activity relationship studies for HEPTs and DABOs as HIV-1 reverse transcriptase inhibitors. Journal of Molecular Modeling, 18, 2185–2198. doi:10.1007/s00894-011-1236-8
   PubMed Web of Science ®Google Scholar
• Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K., & Olson, A. J. (1998). Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. Journal of Computational Chemistry, 19, 1639–1662. doi:10.1002/(SICI)1096-987X(19981115)19:14<1639:AID-JCC10>3.0.CO;2-B
   Web of Science ®Google Scholar
• Nasser, G., Mohammad, G., Araujo, M. C. U., & GalvãO, R. K. H. (2009). QSPR modeling of soil sorption coefficients (KOC) of pesticides using SPA-ANN and SPA-MLR. Journal of Agricultural & Food Chemistry, 57, 7153–7158. doi:10.1021/jf9008839
   PubMed Web of Science ®Google Scholar
• Nguyen, N.-H., Apriletti, J. W., Cunha Lima, S. T., Webb, P., Baxter, J. D., & Scanlan, T. S. (2002). Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. Journal of Medicinal Chemistry, 45, 3310–3320. doi:10.1021/jm0201013
   PubMed Web of Science ®Google Scholar
• Nguyen, N. H., Apriletti, J. W., Baxter, J. D., & Scanlan, T. S. (2005). Hammett analysis of selective thyroid hormone receptor modulators reveals structural and electronic requirements for hormone antagonists. Journal of the American Chemical Society, 127, 4599–4608. doi:10.1021/ja0440093
   PubMed Web of Science ®Google Scholar
• Phillips, J. C., Rosemary, B., Wei, W., James, G., Emad, T., Elizabeth, V., … Klaus, S. (2005). Scalable molecular dynamics with NAMD. Journal of Computational Chemistry, 26, 1781–1802. doi:10.1002/jcc.20289
   PubMed Web of Science ®Google Scholar
• Phys, J. C. (1995). A smooth Particle Mesh Ewald method. Journal of Chemical Physics, 103, 8577–8593. doi:10.1063/1.470117
   Web of Science ®Google Scholar
• Pirhadi, S., & Ghasemi, J. B. (2010). 3D-QSAR analysis of human immunodeficiency virus entry-1 inhibitors by CoMFA and CoMSIA. European Journal of Medicinal Chemistry, 45, 4897–4903. doi:10.1016/j.ejmech.2010.07.062
   PubMed Web of Science ®Google Scholar
• Privalsky, M. L. (2004). The role of corepressors in transcriptional regulation by nuclear hormone receptors. Annual Review of Physiology, 66, 315–360. doi:10.1146/annurev.physiol.66.032802.155556
   PubMed Web of Science ®Google Scholar
• Ram, T., Daga, P. R., Rahul, B., & Javed, I. (2005). 3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases. Bioorganic & Medicinal Chemistry, 13, 4704–4712. doi:10.1016/j.bmc.2005.04.065
   PubMed Web of Science ®Google Scholar
• Ren, Y., Liu, H., Li, S., Yao, X., & Liu, M. (2007). Prediction of binding affinities to beta1 isoform of human thyroid hormone receptor by genetic algorithm and projection pursuit regression. Bioorganic & Medicinal Chemistry Letters, 17, 2474–2482. doi:10.1016/j.bmcl.2007.02.025
   PubMed Web of Science ®Google Scholar
• Ribeiro, R. C. J., Apriletti, J. W., Wagner, R. L., Feng, W., Kushner, P. J., Nilsson, S., … Baxter, J. D. (1998). X-ray crystallographic and functional studies of thyroid hormone receptor. Journal of Steroid Biochemistry & Molecular Biology, 65, 133–141. doi:10.1016/S0960-0760(98)00029-6
   PubMed Web of Science ®Google Scholar
• Schapira, M., Raaka, B. M., Samuels, H. H., & Abagyan, R. (2000). Rational discovery of novel nuclear hormone receptor antagonists. Proceedings of the National Academy of Sciences, 97, 1008–1013. doi:10.1073/pnas.97.3.1008
   PubMed Web of Science ®Google Scholar
• Schueler, P., Schwartz, H., Strait, K., Mariash, C., & Oppenheimer, J. (1990). Binding of 3, 5, 3′-triiodothyronine (T3) and its analogs to the in vitro translational products of c-erbA protooncogenes: Differences in the affinity of the α-and β-forms for the acetic acid analog and failure of the human testis and kidney α-2 products to bind T3. Molecular Endocrinology, 4, 227–234. doi:10.1210/mend-4-2-227
   PubMed Web of Science ®Google Scholar
• Schwartz, H. L., Strait, K. A., Ling, N. C., & Oppenheimer, J. H. (1992). Quantitation of rat tissue thyroid hormone binding receptor isoforms by immunoprecipitation of nuclear triiodothyronine binding capacity. Journal of Biological Chemistry, 267, 11794–11799. http://www.jbc.org/content/267/17/11794.full.pdf+html?sid=4e8e5397-87c3-4bef-a6dd-99b7b86caaa8
   PubMed Web of Science ®Google Scholar
• Shiohara, H., Nakamura, T., Kikuchi, N., Ozawa, T., Nagano, R., Matsuzawa, A., … Hashizume, K. (2012). Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ) agonists for the treatment of dyslipidemia. Bioorganic & Medicinal Chemistry, 20, 3622–3634. doi:10.1016/j.bmc.2012.03.056
   PubMed Web of Science ®Google Scholar
• Shiohara, H., Nakamura, T., Kikuchi, N., Ozawa, T., Matsuzawa, A., Nagano, R., … Hashizume, K. (2013). Design, synthesis, and structure-activity relationship (SAR) of N-[7-(4-hydroxyphenoxy)-6-methylindan-4-yl]malonamic acids as thyroid hormone receptor β (TRβ) selective agonists. Bioorganic & Medicinal Chemistry, 21, 592–607. doi:10.1016/j.bmc.2012.12.002
   PubMed Web of Science ®Google Scholar
• Taylor, A. H., Stephan, Z. F., Steele, R. E., & Wong, N. C. (1997). Beneficial effects of a novel thyromimetic on lipoprotein metabolism. Molecular Pharmacology, 52, 542–547. doi:10.1124/mol.52.3.542
   PubMed Web of Science ®Google Scholar
• Todeschini, R., & Consonni, V. (2000). Handbook of molecular descriptors. Methods & Principles in Medicinal Chemistry, 11. doi: 10.1002/9783527613106
   Google Scholar
• Underwood, A. H., Emmett, J. C., Ellis, D., Flynn, S. B., Leeson, P. D., Benson, M., … Shah, V. P. (1986). A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity. Nature, 324, 425–429. doi:10.1038/324425a0
   PubMed Web of Science ®Google Scholar
• Utiger, R. D. (1995). The thyroid: Physiology, thyrotoxicosis, hypothyroidism, and the painful thyroid. In P. Felig, J. D. Baxter & L. A. Frohman (Eds.), Endocrinology and Metabolism (pp. 435–519). New York, NY: McGraw-Hill.
   Google Scholar
• Vedani, A., Dobler, M., & Lill, M. A. (2006). The challenge of predicting drug toxicity in silico. Basic & Clinical Pharmacology & Toxicology, 99, 195–208. doi:10.1111/j.1742-7843.2006.pto_471.x
   PubMed Web of Science ®Google Scholar
• Vedani, A., Zumstein, M., Lill, M. A., & Ernst, B. (2007). Simulating α/β selectivity at the human thyroid hormone receptor: Consensus scoring using multidimensional QSAR. ChemMedChem, 2, 78–87. doi:10.1002/cmdc.200600212
   PubMed Web of Science ®Google Scholar
• Wagner, R. L., Apriletti, J. W., McGrath, M. E., West, B. L., Baxter, J. D., & Fletterick, R. J. (1995). A structural role for hormone in the thyroid hormone receptor. Nature, 378, 690–697. doi:10.1038/378690a0
   PubMed Web of Science ®Google Scholar
• Wagner, R. L., Huber, B. R., Shiau, A. K., Kelly, A., Cunha Lima, S. T., Scanlan, T. S., … Fletterick, R. J. (2001). Hormone selectivity in thyroid hormone receptors. Molecular Endocrinology, 15, 398–410. doi:10.1210/me.15.3.398
   PubMed Web of Science ®Google Scholar
• Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A., & Case, D. A. (2004). Development and testing of a general amber force field. Journal of Computational Chemistry, 25, 1157–1174. doi:10.1002/jcc.20035
   PubMed Web of Science ®Google Scholar
• Wang, F., Li, Y., Ma, Z., Wang, X., & Wang, Y. (2012). Structural determinants of benzodiazepinedione/peptide-based p53-HDM2 inhibitors using 3D-QSAR, docking and molecular dynamics. Journal of Molecular Modeling, 18, 295–306. doi:10.1007/s00894-011-1041-4
   PubMed Web of Science ®Google Scholar
• Wang, F., Ma, Z., Li, Y., Wang, J., & Wang, Y. (2012). Structural requirements of pyrimidine, thienopyridine and ureido thiophene carboxamide-based inhibitors of the checkpoint kinase 1: QSAR, docking, molecular dynamics analysis. Journal of Molecular Modeling, 18, 3227–3242. doi:10.1007/s00894-011-1321-z
   PubMed Web of Science ®Google Scholar
• Wang, F., Ma, Z., Li, Y., Zhu, S., Xiao, Z., Zhang, H., & Wang, Y. (2011). Development of in silico models for pyrazoles and pyrimidine derivatives as cyclin-dependent kinase 2 inhibitors. Journal of Molecular Graphics & Modelling, 30, 67–81. doi:10.1016/j.jmgm.2011.06.006
   PubMed Web of Science ®Google Scholar
• Wang, Y., Li, Y., Ding, J., Jiang, Z., & Chang, Y. (2008). Estimation of bioconcentration factors using molecular electro-topological state and flexibility. Sar & Qsar in Environmental Research, 19, 375–395. doi:10.1080/10629360802085058
   PubMed Web of Science ®Google Scholar
• Weatherman, R. V., Fletterick, R. J., & Scanlan, T. S. (1999). Nuclear-receptor ligands and ligand-binding domains. Annual Review of Biochemistry, 68, 559–581. doi:10.1146/annurev.biochem.68.1.559
   PubMed Web of Science ®Google Scholar
• Webb, P., Nguyen, N.-H., Chiellini, G., Yoshihara, H. A., Lima, S. T. C., Apriletti, J. W., … Goede, P. (2002). Design of thyroid hormone receptor antagonists from first principles. The Journal of Steroid Biochemistry and Molecular Biology, 83, 59–73. doi:10.1016/S0960-0760(02)00270-4
   PubMed Web of Science ®Google Scholar
• Xu, J., & Li, Q. (2003). Review of the in vivo functions of the p160 steroid receptor coactivator family. Molecular Endocrinology, 17, 1681–1692. doi:10.1210/me.2003-0116
   PubMed Web of Science ®Google Scholar